ANAHEIM, Calif.—Gencor Pacific announced two toxicity studies were recently completed on its patented Caralluma fimbriata extract, SLIMALUMA™. The studies—a chromosomal aberration trial and a teratogenicity study—were conducted in GLP (good laboratory practice)-certified institutions. According to Gencor, the findings support SLIMALUMA’s safety for consumption by both the general public and pregnant women. SLIMALUMA was previously tested in an acute oral toxicity study, a sub-chronic toxicity study and a mutagenicity study.